StockWatch
·

DAVITA INC. Q2 FY26 Results

DVAQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue3.6K4.1%5.2%
Total Income3.6K4.1%5.2%
Expenditure3.0K1.4%4.7%
PBT435.0127.5%17.9%
Net Profit265.4034.4%33.1%
OPM16.29%2.18pp0.38pp
NPM7.47%1.68pp1.57pp
EPS4.1039.9%56.5%
View full financials

DaVita Inc. Reports Q2 2026 Financial and Operating Results

05 Aug 2026 · 5 Aug, 1:46 am

Summary

DaVita Inc. announced its financial and operating results for the second quarter ended June 30, 2026. Consolidated revenues for the quarter were $3.554 billion, with operating income reported at $579 million and diluted earnings per share at $4.02. The company generated $490 million in operating cash flow and $256 million in free cash flow. Management highlighted the positive quarter for both patient outcomes and financial results, emphasizing a continued strategic focus on innovations in kidney dialysis.

Key Highlights

  1. 1

    Consolidated revenues for the quarter ended June 30, 2026, were $3.554 billion.

  2. 2

    Operating income for the quarter was $579 million, with an operating margin of 16.3%.

  3. 3

    Diluted earnings per share for the quarter reached $4.02.

  4. 4

    Operating cash flow for the quarter was $490 million, and free cash flow was $256 million.

  5. 5

    The company repurchased 2.2 million shares of common stock for $348 million during the quarter.

  6. 6

    As of June 30, 2026, DaVita provided dialysis services to approximately 298,500 patients at 3,266 outpatient dialysis centers.

  7. 7

    As of June 30, 2026, the company had approximately 64,900 patients in risk-based integrated care arrangements representing approximately $5.8 billion in annualized medical spend.

Management Comments

J

Javier Rodriguez

Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results. As we look to the rest of the year, we maintain our strategic focus on exciting new innovations in kidney dialysis to enhance the lives of our patients.

Informational and educational content only. Not investment advice.